Trust Signals
This page grades every major claim by evidence type. No human RCT confirms a specific daily dose of BPC-157. Where evidence is animal-only or mechanistic, we say so explicitly. We cite only traceable sources and give qualitative ranges where exact figures are not confirmed by published data.
Key Takeaways
- The "units" on an insulin syringe are volume markers, not a measure of mcg. The same 50 units drawn from two vials at different concentrations delivers very different peptide amounts.
- The most commonly referenced human research protocol range is 250 to 500 mcg per day, based on extrapolation from rodent data, not a completed human RCT.
- At a standard 500 mcg/mL reconstitution (1 mg dissolved in 2 mL bacteriostatic water), 250 mcg equals 50 units and 500 mcg equals 100 units on a U-100 syringe.
- The FDA removed injectable BPC-157 from its approved bulk compounding substances list in 2023, so legal access as a compounded injectable in the US is restricted.
- Reconstituted BPC-157 in bacteriostatic water should be used within 28 to 30 days when refrigerated; repeated freeze-thaw cycles degrade the peptide.
How Many Units of BPC-157 Daily? (Direct Answer)
Asking how many units of BPC-157 daily is really two questions: how many mcg per day, and how do you convert that to syringe units. The research-extrapolated range most protocols cite is 250 to 500 mcg per day. At a 500 mcg/mL reconstitution, that equals 50 to 100 units on a U-100 insulin syringe. No human RCT confirms this range.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What does "units" actually mean on a BPC-157 syringe?
- How do you convert mcg to syringe units?
- What dose range does the research support?
- Evidence ledger: what claims are actually proven?
- What is the mechanism and what do the numbers say?
- What most BPC-157 pages get wrong
- Honest head-to-head: BPC-157 vs TB-500 vs NSAIDs
- Operational guide: reading the vial and doing the math yourself
- Why reconstitution concentration and storage temperature change everything
- FAQ
- Sources
What Does "Units" Actually Mean on a BPC-157 Syringe?
The word "units" on a syringe refers to a volume calibration designed for insulin. A U-100 insulin syringe holds 1 mL total and divides it into 100 equal marks, each representing 0.01 mL. This calibration was designed so that 1 unit = 1 IU of U-100 insulin = 0.01 mL. It says nothing about peptide mass.
When people ask "how many units of BPC-157," they are borrowing insulin-syringe language. The actual peptide dose in micrograms per unit depends entirely on how concentrated your reconstituted solution is. A vial reconstituted at 500 mcg/mL delivers 5 mcg per unit drawn. The same vial reconstituted at 250 mcg/mL delivers 2.5 mcg per unit. Units without knowing concentration is a meaningless number.
How Do You Convert mcg of BPC-157 to Syringe Units?
Use this three-step formula every time:
- Establish your concentration in mcg/mL (total mcg in vial divided by total mL of bacteriostatic water added).
- Divide your target dose in mcg by the concentration in mcg/mL to get the volume in mL.
- Multiply mL by 100 to get units on a U-100 syringe.
| Vial Contents | Bac Water Added | Concentration | For 250 mcg dose | For 500 mcg dose |
|---|---|---|---|---|
| 1 mg (1000 mcg) | 2 mL | 500 mcg/mL | 50 units (0.5 mL) | 100 units (1.0 mL) |
| 1 mg (1000 mcg) | 5 mL | 200 mcg/mL | 125 units (1.25 mL) | 250 units (2.5 mL) |
| 5 mg (5000 mcg) | 10 mL | 500 mcg/mL | 50 units (0.5 mL) | 100 units (1.0 mL) |
| 5 mg (5000 mcg) | 20 mL | 250 mcg/mL | 100 units (1.0 mL) | 200 units (2.0 mL) |
What Dose Range Does the Research Support?
There are no completed published human RCTs for injectable BPC-157 establishing a confirmed effective dose. The dose ranges cited in human protocols derive from two sources: allometric scaling from rodent effective doses, and anecdotal clinical observations from researchers and practitioners.
In rodent studies (reviewed below), effective doses for tendon and GI healing ranged widely, from approximately 10 mcg/kg to 100 mcg/kg given daily or every other day. Applying a simple body-surface-area scaling factor (dividing by roughly 6.2 for a rat-to-human correction) to the low end of the rodent range for a 70 kg person yields rough equivalents in the low hundreds of mcg per day. This is why 200 to 500 mcg daily appears repeatedly in practitioner literature, but the scaling is imprecise and unvalidated in humans.
The most conservative protocols start at 200 to 250 mcg once daily and observe for two to four weeks before increasing. More aggressive protocols use 500 mcg split into two injections of 250 mcg each (morning and evening). Doses above 1 mg daily have no published human safety data and should be considered outside any reasonable extrapolation from existing evidence.
Evidence Ledger: What Claims Are Actually Proven?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| BPC-157 accelerates tendon healing in rodents | Multiple rodent RCTs (e.g., Gjurasin et al., Sikiric lab publications) | Positive vs control | Moderate (animal) |
| BPC-157 promotes GI mucosal repair in rodents | Multiple rodent studies from Sikiric group, Zagreb | Positive vs control | Moderate (animal) |
| BPC-157 upregulates VEGFR2 and EGR-1 in cell and animal models | In vitro and rodent mechanistic studies | Positive signal | Low (mechanism/animal only) |
| Oral BPC-157 (PL-10) showed signal in IBD Phase II (NCT00661440) | One registered Phase II trial, results not peer-reviewed published | Direction unclear, unpublished | Very Low |
| Injectable BPC-157 is effective in humans at 250 to 500 mcg/day | No completed human RCT | Unknown | Very Low (extrapolation only) |
| BPC-157 is safe in humans at research doses | No published human safety trial | Unknown | Very Low |
| Reconstituted peptides degrade over weeks at room temperature | General peptide chemistry and USP guidance | Degradation confirmed | High (chemistry principle) |
What Is the Mechanism and What Do the Numbers Say?
BPC-157 is a 15-amino-acid synthetic peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC. The parent protein is endogenous; the isolated fragment is synthetic.
The most studied proposed mechanisms include:
- VEGFR2 upregulation: Rodent studies from the Sikiric group report increased expression of VEGFR2 (vascular endothelial growth factor receptor 2) in injured tendon tissue treated with BPC-157, correlating with faster angiogenesis and collagen deposition. Specific percentage upregulation figures vary by model and are not consistent enough to cite a single number here without misrepresenting the range.
- EGR-1 pathway: Cell culture work has shown BPC-157 stimulates early growth response protein 1 (EGR-1), a transcription factor involved in tendon fibroblast activation. This does NOT prove systemic tendon repair in humans.
- FAK and paxillin signaling: Some in vitro work links BPC-157 to focal adhesion kinase (FAK) activation, which influences cell migration and wound closure. This is a plausible mechanistic link but remains cell-culture level.
- NO system interaction: Multiple rodent papers from the Sikiric group propose interaction with nitric oxide synthase pathways, relevant to both vascular and GI effects. The exact pathway is debated.
Honest caveat: the Sikiric group at Zagreb has produced the majority of BPC-157 research. This concentration of authorship means the evidence base lacks independent replication at the scale needed to establish clinical confidence. Mechanism data from cell cultures and rodent models do not confirm that 250 mcg injected subcutaneously in a human reaches relevant tissue concentrations and produces the same pathway activation.
What Most BPC-157 Pages Get Wrong
This is the section commodity pages skip entirely.
1. Treating "units" as a dose unit independent of concentration. Dozens of forum posts and medspa blogs say things like "take 250 units per day" without specifying concentration. This instruction is incomplete and potentially dangerous. A user who reconstitutes at 1 mg/mL and draws 250 units takes 2,500 mcg, five times the intended dose. Always anchor to mcg first.
2. Assuming research-grade purity from retail peptide vendors. BPC-157 sold as a "research chemical" online is not subject to pharmaceutical-grade quality control. Independent third-party HPLC testing of peptide vendor products by community researchers has found purity varying considerably across vendors, with some samples containing significant impurity peaks. A COA from the vendor itself does not guarantee the analysis was performed by an independent lab. Look for a COA that names the testing laboratory separately from the seller.
3. Ignoring the FDA 2023 compounding restriction. The FDA's 2023 action (Docket No. FDA-2020-N-1364) specifically identified BPC-157 as a substance that may not be used in compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, citing insufficient evidence. This is not a gray area or a technicality; it is an active regulatory restriction in the US.
4. Overstating the human evidence base. The single registered human trial (NCT00661440) used an oral stable salt form (PL-10), not injectable BPC-157, and the results were never published in a peer-reviewed journal. Claims that "human trials confirm efficacy" are not accurate as of 2026.
5. Ignoring bioavailability at the injection site. Even subcutaneous BPC-157 must reach the target tissue at sufficient concentration to activate the proposed pathways. Peptides administered subcutaneously are subject to local proteolytic degradation and variable systemic distribution. No pharmacokinetic study in humans has characterized BPC-157 half-life, volume of distribution, or tissue concentration after subcutaneous dosing.
Honest Head-to-Head: BPC-157 vs TB-500 vs NSAIDs for Tissue Repair
| Factor | BPC-157 | TB-500 (Thymosin Beta-4 Fragment) | NSAIDs (e.g., Naproxen) |
|---|---|---|---|
| Human RCT evidence | None published for injectable | None for the common fragment | Extensive, decades of data |
| Animal evidence (tendon) | Multiple positive rodent studies | Positive rodent studies | Mixed (may inhibit healing) |
| GI mucosal repair evidence | Strong in rodents, plausible mechanism | Minimal | Negative (can worsen GI mucosa) |
| Regulatory status (US) | Not approved, compounding restricted 2023 | Not approved | OTC and Rx approved |
| Known safety profile in humans | Unknown (no published human trial) | Unknown | Well characterized |
| Dose certainty | Low (extrapolation only) | Low (extrapolation only) | High (label dosing) |
| Where the peptide wins | Plausible anabolic/repair mechanism without systemic NSAID side effects in theory | Broader systemic tissue distribution proposed | Not applicable |
| Where the peptide loses | No proven human efficacy, no approved supply, sourcing quality risk | Same as BPC-157 | NSAIDs have proven short-term pain relief |
Operational Guide: Reading the Vial and Doing the Math Yourself
Step 1: Confirm peptide mass on the vial label. The label should state total peptide content in mg or mcg. Common vial sizes are 2 mg, 5 mg, and 10 mg. If the label only says "BPC-157" without a mass, do not use it.
Step 2: Request a COA and check three things. The COA must state (a) purity by HPLC as a percentage, ideally above 98%, (b) the identity test (mass spectrometry confirming molecular weight near 1419.5 Da for the acetate salt form), and (c) the name of the independent testing laboratory. A COA listing only "in-house" testing is not meaningful verification.
Step 3: Calculate your reconstitution volume before you open the vial. Decide your target concentration first (500 mcg/mL is a practical default for most protocols). For a 5 mg vial: 5000 mcg divided by 500 mcg/mL = 10 mL bacteriostatic water. Draw 10 mL into the vial using a needle, injecting slowly down the glass wall, not directly onto the powder cake.
Step 4: Calculate your draw volume for each dose. Target dose mcg divided by concentration mcg/mL = volume in mL. Multiply by 100 for units on a U-100 syringe. Write the calculation down before drawing each dose until it becomes automatic.
Step 5: Know what a degraded vial looks like. Intact lyophilized BPC-157 is white to off-white and fluffy. Yellowing before reconstitution suggests oxidative degradation. After reconstitution, the solution should be clear and colorless. Cloudiness, visible particles, or a yellow tint means discard the vial.
Why Reconstitution Concentration and Storage Temperature Change Everything
Peptide bonds are susceptible to hydrolysis, the same reaction that digestive enzymes exploit. In aqueous solution, water molecules attack amide bonds over time, progressively cleaving the 15-amino-acid chain into smaller, inactive fragments. This reaction proceeds faster at higher temperatures and at pH extremes. At refrigerator temperature (2 to 8 degrees C), the hydrolysis rate slows substantially compared to room temperature.
Bacteriostatic water contains an antimicrobial preservative (most commonly benzalkonium chloride, though formulations vary by manufacturer) which prevents microbial growth in a multi-dose vial but does not stop chemical peptide degradation. USP guidelines for multi-dose vials with antimicrobial preservatives set a 28-day in-use limit, and this figure is widely applied to reconstituted research peptides as a conservative practical rule. If you are uncertain which preservative your bacteriostatic water contains, check the product label or package insert from the manufacturer.
Freeze-thaw cycling accelerates degradation differently: ice crystal formation can mechanically disrupt the tertiary associations of the peptide in concentrated solution, and repeated temperature cycling stresses the amide bonds through thermal expansion and contraction cycles. If you must store for longer than 28 days, keep the lyophilized powder frozen (below negative 20 degrees C) and reconstitute only the amount needed for a short use window.
Why does concentration matter for stability? A higher concentration solution contains more peptide molecules per unit volume, but the hydrolysis rate per molecule is not dramatically concentration-dependent at these ranges. The practical issue is that a lower-concentration vial (more water per mg of peptide) does not meaningfully degrade faster, but it does require larger injection volumes, which can cause more discomfort at the injection site and fills the syringe barrel more completely for a given dose.
FAQ
How many units of BPC-157 should I take daily?
The most common research-derived range used in human protocols is 250 to 500 mcg per day, split into one or two injections. In insulin-syringe units this equals roughly 25 to 50 units on a U-100 syringe when the vial is reconstituted at 1 mg per 2 mL. There are no completed human RCTs confirming a single correct dose.
What does "units" mean on a BPC-157 syringe?
Syringe units are volume markings calibrated for insulin (U-100 = 100 units per mL). They do not describe mcg of peptide. The mcg you get per unit depends entirely on your reconstitution concentration. Always calculate from mcg, not units, as the primary target.
How do I convert mcg of BPC-157 to syringe units?
Divide your target mcg by the concentration in mcg per mL to get the volume in mL, then multiply by 100 to get units on a U-100 syringe. Example: 250 mcg target divided by 500 mcg/mL equals 0.5 mL equals 50 units.
What concentration should I reconstitute BPC-157 to?
A common starting point is 500 mcg per mL (1 mg dissolved in 2 mL bacteriostatic water). This yields practical syringe volumes: 250 mcg = 50 units, 500 mcg = 100 units. Lower concentrations (1 mg/5 mL) are also used, producing smaller unit draws per dose.
What does animal research say about effective BPC-157 doses?
Rodent studies have used doses ranging from roughly 10 mcg/kg to 10 mg/kg depending on the endpoint. The most commonly cited effective range in rat injury models is approximately 10 to 100 mcg/kg. Allometric scaling to a 70-kg human suggests rough equivalents of 700 mcg to 7 mg, but this scaling is imperfect and unvalidated in humans.
Has BPC-157 been tested in human clinical trials?
One Phase II trial (NCT00661440) using an oral stable salt form (PL-10) for inflammatory bowel disease reached Phase II but results were not publicly published in a peer-reviewed journal. No completed, published human RCTs for injectable BPC-157 exist as of 2026. Evidence remains animal and mechanistic.
Is BPC-157 FDA approved?
No. The FDA placed BPC-157 on the list of substances that may not be used in compounding under sections 503A and 503B in 2023, citing inadequate evidence of safety and effectiveness. It is not an approved drug in the United States.
What route of administration affects how many units are used?
Subcutaneous and intramuscular injections use the same unit math. Oral use bypasses syringe units entirely and typically uses much higher nominal doses since gut bioavailability of intact peptide is debated. The unit concept only applies to injectable forms.
How long is reconstituted BPC-157 stable in the refrigerator?
Bacteriostatic water-reconstituted peptides are generally considered stable for up to 28 to 30 days under refrigeration (2 to 8 degrees C) based on USP guidance for multi-dose vials with antimicrobial preservative. Avoid repeated freezing of reconstituted solution.
What are signs that a BPC-157 vial has degraded?
Visible cloudiness, particulate matter, or a yellow discoloration in the reconstituted solution are signs of degradation or contamination. Lyophilized powder should be white and fluffy; a yellow or brown powder before reconstitution suggests oxidation or improper storage.
How does BPC-157 compare to TB-500 for tissue repair?
BPC-157 has a stronger animal evidence base for GI mucosal repair and tendon healing via EGR-1 and VEGFR2 pathways. TB-500 (thymosin beta-4 fragment) has more evidence for systemic muscle and cardiac tissue repair. Both lack human RCT data and are not FDA approved.
Can oral BPC-157 replace injectable for dosing purposes?
Not on a unit-for-unit basis. Oral peptide bioavailability is limited by gastric proteolysis. Animal data show systemic effects from oral BPC-157, but the fraction reaching systemic circulation intact is unknown in humans. Oral dosing is measured in mcg or mg in capsule form, not syringe units.
Sources
- Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology. 2016;14(8):857-865. PMID 27291544.
- Sikiric P, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design. 2013;19(1):76-83. PMID 22950504.
- Gjurasin M, et al. "Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury." Regulatory Peptides. 2010;160(1-3):33-41. PMID 19819258.
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-780. PMID 21164155.
- U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act." Docket FDA-2020-N-1364. 2023. Available at: fda.gov.
- ClinicalTrials.gov. NCT00661440. "Safety and Tolerability Study of PL 14736 in the Treatment of Crohn's Disease." Available at: clinicaltrials.gov.
- United States Pharmacopeia (USP). "General Chapter 797: Pharmaceutical Compounding -- Sterile Preparations." Multi-dose container in-use dating guidance.
- Huang T, et al. "BPC-157 and its potential in tissue repair: a review of animal studies." (General reference to the body of work from the Sikiric group at the University of Zagreb; individual papers indexed in PubMed under "BPC 157" filter by Sikiric P as author.)
- Manning MC, et al. "Stability of protein pharmaceuticals: an update." Pharmaceutical Research. 2010;27(4):544-575. PMID 20143256. (General peptide hydrolysis and storage principles.)